0107 ECP Endeavor
BioCentury & Getty Images
Emerging Company Profile
Impact founder Hood launches Endeavor with $62M to address pulmonary diseases
Emerging Company Profile: Endeavor is starting with a hedgehog inhibitor from Eli Lilly in IPF
With $62 million in series A financing, Endeavor is planning two Phase II clinical trials of a Lilly small molecule to treat IPF.
By Danielle
Read the full 580 word article